Loading clinical trials...
Loading clinical trials...
A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection
Conditions
Interventions
PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Locations
1
Iran
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Tehran, Tehran Province, Iran
Start Date
March 1, 2007
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
September 17, 2009
NCT06379789
NCT07226206
NCT05987449
NCT06953479
NCT06008938
NCT04645199
Lead Sponsor
Baqiyatallah Medical Sciences University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions